| Assay | Target | IC₅₀ / EC₅₀ | Comments | |-------|--------|------------|----------| | Fluorescence‑based ATPase assay | NLRP3 NACHT domain | 12 nM | Competitive with ATP, Ki ≈ 8 nM | | AlphaScreen BRD4‑acetyl‑lysine interaction | BET bromodomain | 48 nM | Selective over BRD3/BRD2 (2‑fold) | | Calcium flux (CXCR2) | CXCR2 | 1.1 µM | Weak; likely off‑target | | Cytokine release (LPS‑primed THP‑1) | IL‑1β, IL‑18 | 30‑70 nM (IC₅₀) | Complete blockade of ASC speck formation | | Cell‑viability (MDA‑MB‑231, MV4‑11) | Cancer cell lines | 0.3‑1 µM (GI₅₀) | Cytostatic at low µM concentrations |
The "iptd-694" feature focuses on improving network interface management for enhanced performance, security, and usability. This feature aims to provide more granular control over network interfaces, better traffic management, and improved error handling. iptd-694
These codes are often linked to a specific lead actress or theme featured in the production. 🔬 Alternative Scientific Meaning | Assay | Target | IC₅₀ / EC₅₀
The specific mechanism of action of IPTD-694 is not yet fully understood, but it is believed to involve the modulation of the glycosphingolipid (GSL) metabolism pathway. In rare genetic disorders such as Fabry disease and Gaucher disease, there is an accumulation of GSLs in various tissues due to deficiencies in specific enzymes involved in their breakdown. IPTD-694 is thought to interact with this pathway to restore normal GSL metabolism and reduce the accumulation of toxic intermediates. One of the earliest studies to investigate the
One of the earliest studies to investigate the efficacy of IPTD-694 was a phase 1 clinical trial conducted in patients with Fabry disease. The study, known as a randomized, double-blind, placebo-controlled trial (RCT), enrolled 12 patients who received either IPTD-694 or a placebo over a 28-day period. Results from the study showed that IPTD-694 significantly reduced the levels of globotriaosylceramide (Gb3), a key GSL intermediate, in patients' plasma.